Know Labs 将来の成長

Future 基準チェック /06

Know Labsの収益は年間13.7%で減少すると予測されていますが、年間収益は年間150.1%で増加すると予想されています。EPS は年間15.9%で減少すると予想されています。

主要情報

-13.7%

収益成長率

-15.9%

EPS成長率

Medical Equipment 収益成長	17.1%
収益成長率	150.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 Aug 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

NYSEAM:KNW - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2026	6	-22	N/A	-20	1
9/30/2025	N/A	-19	N/A	-15	1
9/30/2024	N/A	-17	-13	-13	N/A
6/30/2024	N/A	-16	-11	-11	N/A
3/31/2024	N/A	-21	-11	-11	N/A
12/31/2023	N/A	-20	-11	-11	N/A
9/30/2023	N/A	-20	-10	-10	N/A
6/30/2023	N/A	-23	-12	-12	N/A
3/31/2023	N/A	-17	-12	-12	N/A
12/31/2022	0	-19	-8	-8	N/A
9/30/2022	4	-20	-8	-7	N/A
6/30/2022	4	-22	-6	-5	N/A
3/31/2022	4	-26	-6	-5	N/A
12/31/2021	4	-25	-8	-7	N/A
9/30/2021	N/A	-25	-7	-7	N/A
6/30/2021	N/A	-22	-6	-6	N/A
3/31/2021	N/A	-18	-6	-5	N/A
12/31/2020	0	-16	-5	-5	N/A
9/30/2020	0	-14	-4	-4	N/A
6/30/2020	0	-12	-4	-4	N/A
3/31/2020	1	-12	-4	-4	N/A
12/31/2019	1	-10	-3	-3	N/A
9/30/2019	2	-8	-3	-3	N/A
6/30/2019	2	-5	-2	-2	N/A
3/31/2019	3	-4	-2	-2	N/A
12/31/2018	4	-3	-1	-1	N/A
9/30/2018	4	-3	-1	-1	N/A
6/30/2018	5	-3	N/A	-1	N/A
3/31/2018	5	-2	N/A	-1	N/A
12/31/2017	5	-2	N/A	-1	N/A
9/30/2017	5	-4	N/A	-1	N/A
6/30/2017	5	-4	N/A	-2	N/A
3/31/2017	6	-3	N/A	-2	N/A
12/31/2016	6	-2	N/A	-3	N/A
9/30/2016	6	-2	N/A	-3	N/A
6/30/2016	6	-3	N/A	-2	N/A
3/31/2016	6	-4	N/A	-1	N/A
12/31/2015	6	-1	N/A	0	N/A
9/30/2015	6	-3	N/A	0	N/A
6/30/2015	7	0	N/A	-1	N/A
3/31/2015	7	1	N/A	-1	N/A
12/31/2014	8	-3	N/A	-2	N/A
9/30/2014	8	-1	N/A	-1	N/A
6/30/2014	8	-2	N/A	-2	N/A
3/30/2014	8	-6	N/A	-3	N/A
12/31/2013	8	-7	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: KNW今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: KNW今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: KNW今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: KNW来年は収益がないと予測されています。

高い収益成長: KNW来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: KNWの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Know Labs 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Know Labs, Inc Announces Executive Appointments

Know Labs Receives Non Compliance Letter from NYSE American Regarding Sections 1003(a)(ii) and 1003(a)(iii)

High number of new and inexperienced directors

Know Labs, Inc. Announces Board and Committee Changes

Know Labs, Inc. has completed a Composite Units Offering in the amount of $3.445 million.

Know Labs, Inc., Annual General Meeting, Sep 26, 2024

Know Labs, Inc. Publishes Clinical Results in Leading Diabetes Journal

Know Labs, Inc. Announces Further Interim Results from a Clinical Research Study

Know Labs, Inc. Announces the Appointment of Chris Somogyi as President, International

Know Labs, Inc. to Present Clinical Research At the 2024 American Association of Clinical Endocrinology Annual Meeting

Know Labs, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Know Labs, Inc. Announces Interim Results from its Most Recent Clinical Research Study

Know Labs, Inc. Announces Board Appointments

Know Labs, Inc. Expands Board of Directors

Know Labs, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Know Labs, Inc., Annual General Meeting, Sep 22, 2023

Know Labs, Inc. Demonstrates Improved Accuracy of Machine Learning Model for Non-Invasive Glucose Monitor

Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring

Know Labs, Inc. Furthers External Validation of Bio-RFID(TM) Technology with Study Published in Sensors Journal

Know Labs, Inc. Study Validates Technical Feasibility of Its Novel Sensor for Non-Invasive Glucose Monitoring

Know Labs, Inc. Announces Changes to Executive Leadership Team

Know Labs, Inc. Announces Management Changes

Know Labs Common Stock Deleted from OTC Equity

Know Labs, Inc. has completed an IPO in the amount of $7.2 million.

Know Labs, Inc., Annual General Meeting, Sep 15, 2022

Know Labs, Inc. Announces Executive Appointments

Know Labs, Inc. Announces Executive Appointments

Know Labs Outlines Preparations for Pre-Submission Meeting with FDA

Know Labs, Inc. announced delayed 10-Q filing

Know Labs, Inc. Receives IRB Approval to Begin Internal Clinical Trial of Non-Invasive Glucose Monitoring Technology Bio-RFID™

Know Labs, Inc. Announces Introduction of New KnowU™ Diagnostic Device

Know Labs Receives New Patent for Its Non-Invasive Diagnostic Technology Platform, Bringing Patents Issued and Pending to Nearly 60

Know Labs Announces Successful Results from Pre-Clinical Study Validating Bio-RFID™ Platform Technology

Know Labs, Inc. announced that it has received $14.279 million in funding

Texas Biomedical Research Institute Issues Preliminary Results for Know Labs, Inc.'s Particle Bulb's Ability to Inactivate the SARS-CoV-2 Virus

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘